This report details the case of a 69-year-old female patient diagnosed with endometrial clear-cell carcinoma (Type II EC), characterized by negative programmed death ligand 1 (PD-L1) expression, low MSI score, low tumor mutational burden (TMB), and low HER2 expression. Here, ERBB2 is linked to neoplasm.